Company Overview
Microbot Medical Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry, where it develops advanced robotic technology to transform endovascular procedures. The company's core business involves offering the LIBERTY system, an endovascular robotic surgical platform that enables physicians to perform catheter-based procedures remotely, outside the immediate catheterization area. This medical device company maintains a market capitalization of $169.91M and employs a workforce of 20 individuals to execute its operational strategy. The market cap figure indicates that the company possesses a significant valuation relative to its small employee base, suggesting that the market prices the enterprise based on its intangible assets, proprietary technology, and potential future revenue streams rather than current operational scale or revenue volume, which are not currently reported.
Financial Health
Microbot Medical Inc. reports a net income of $-13,070,000 and an EBITDA of $-13,972,000 over the trailing twelve months, while the specific revenue figure is not available in the provided data. The substantial gap between the reported net income and the negative EBITDA, combined with the absence of revenue data, reveals a cost structure where operating expenses heavily outweigh any generated income, resulting in a net loss that directly impacts the bottom line. The company generated free cash flow of $-6,286,875, which indicates a current state of negative cash generation that limits immediate financial flexibility for capital expenditures or unexpected opportunities without external financing. Regarding profitability margins, the company records a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, levels that signify the company is currently operating at a loss on a percentage basis and has not yet achieved profitability on a per-unit or per-revenue-dollar basis. The balance sheet shows a cash position of $80.16M against a total debt level of $899,000, resulting in a debt-to-equity ratio of 1.15, which suggests the company carries more debt relative to equity than is typical for a cash-rich entity, though the absolute debt amount is relatively low. Despite the high debt-to-equity metric, the current ratio stands at 27.53, a figure that indicates exceptional short-term liquidity and a massive surplus of current assets over current liabilities, ensuring the ability to meet short-term obligations. Return on Equity is reported at -31.9% and Return on Assets is -20.2%, metrics that reveal management effectiveness is currently challenged by the need to generate positive returns on the substantial cash reserves and asset base to reverse the negative equity and asset yields.
Valuation Assessment
The valuation metrics for Microbot Medical Inc. include a trailing P/E ratio that is listed as N/A and a forward P/E of -7.23, a discrepancy that implies the market expects earnings to improve from the current negative baseline, although the negative forward multiple itself reflects the anticipated continued losses in the near term. The price-to-book ratio is 2.13, indicating that the market values the company at more than double its book value, which suggests a premium is being placed on the company's intangible assets, such as its robotic technology and intellectual property, rather than its tangible net worth. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -6.49, provide context that the valuation is detached from traditional sales-based or earnings-based multiples due to the lack of profitability. The stock has traded within a range defined by a 52-week high of $4.67 and a 52-week low of $1.35, placing the current price trajectory within a wide band of volatility typical for early-stage medical device companies. The beta value of 1.23 indicates that the stock's price volatility is 23% higher than the broader market, reflecting the higher risk profile associated with small-cap medical technology firms that have yet to demonstrate consistent profitability.
Growth & Income
The growth profile for Microbot Medical Inc. is characterized by revenue growth and earnings growth rates that are both listed as N/A, precluding a direct comparison of whether earnings are growing faster or slower than revenue at this specific moment. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it maintain a payout ratio, recorded as 0.0%, meaning all available earnings are theoretically available for reinvestment, though currently negative, into the growth of the LIBERTY robotic system. Consequently, the company's strategy focuses on reinvesting its substantial cash reserves into research, development, and market expansion rather than returning capital to shareholders through dividend payments. The overall growth and income profile for Microbot Medical Inc. is currently defined by a lack of historical revenue data and a complete absence of dividend income, relying entirely on future operational success to drive value creation for investors.